Natalie Prinzi Selected Research

Natalie Prinzi Research Topics

Disease

21	Neoplasms (Cancer) 02/2024 - 01/2014
15	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2023 - 10/2016
5	Disease Progression 01/2022 - 09/2019
4	Merkel Cell Carcinoma 01/2021 - 10/2018
3	Thyroid Neoplasms (Thyroid Cancer) 01/2021 - 01/2015
3	Melanoma (Melanoma, Malignant) 01/2018 - 09/2014
2	Adenocarcinoma 09/2022 - 01/2018
2	Obesity 12/2021 - 01/2021
2	Skin Neoplasms (Skin Cancer) 01/2021 - 01/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 04/2019 - 01/2018
2	Papillary Thyroid Cancer 01/2015 - 11/2012
2	Ovarian Neoplasms (Ovarian Cancer) 01/2015 - 01/2014
2	Breast Neoplasms (Breast Cancer) 01/2014 - 07/2012
1	COVID-19 01/2023
1	Pneumonia (Pneumonitis) 01/2023
1	Small Cell Carcinoma 09/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2022
1	Carcinoid Tumor (Carcinoid) 09/2022
1	Overweight 12/2021
1	Vitamin D Deficiency 01/2021
1	Malnutrition (Nutritional Deficiencies) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Diarrhea 08/2020
1	Short Bowel Syndrome 08/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Gallstones (Gallstone) 01/2020
1	Fistula 11/2019
1	Pancreatic Fistula (Pancreatic Fistulas) 11/2019
1	Colorectal Neoplasms (Colorectal Cancer) 09/2019
1	Anemia 04/2019
1	Febrile Neutropenia 04/2019
1	Neutropenia 04/2019
1	Nausea 04/2019
1	Cholelithiasis 04/2019
1	Margins of Excision 01/2019
1	Primitive Neuroectodermal Tumors (PNET) 01/2018
1	Hyperglycemia 01/2018
1	Glioblastoma (Glioblastoma Multiforme) 01/2018
1	Endemic Goiter 06/2016

Drug/Important Bio-Agent (IBA)

6	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022 - 08/2017
5	Metformin (Glucophage)FDA LinkGeneric 12/2023 - 08/2017
5	lanreotide (Somatuline)FDA Link 12/2023 - 08/2017
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2014
3	Peptide Receptors (Peptide Receptor)IBA 01/2022 - 10/2016
3	Aurora KinasesIBA 05/2016 - 10/2014
2	Radioisotopes (Radionuclides)IBA 01/2022 - 10/2016
2	IodineIBA 01/2021 - 06/2016
2	avelumabIBA 01/2021 - 01/2021
2	Antineoplastic Agents (Antineoplastics)IBA 08/2020 - 01/2020
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2018
2	Octreotide (Sandostatin)FDA LinkGeneric 04/2019 - 01/2018
2	Everolimus FDA Link 01/2018 - 08/2017
2	AutoantibodiesIBA 01/2015 - 01/2014
2	Fertility AgentsIBA 09/2014 - 01/2014
2	Hormones (Hormone)IBA 09/2014 - 07/2012
1	CholesterolIBA 12/2023
1	cabozantinibIBA 09/2023
1	chlorambucil-oleic acid conjugateIBA 09/2022
1	Environmental Pollutants (Pollutants, Environmental)IBA 01/2021
1	Histocompatibility Antigens Class IIBA 01/2021
1	B7-H1 AntigenIBA 01/2021
1	CytokinesIBA 01/2021
1	XenobioticsIBA 01/2021
1	SeleniumIBA 01/2021
1	LeptinIBA 01/2021
1	Insulin (Novolin)FDA Link 01/2021
1	AntidiarrhealsIBA 08/2020
1	Bile Acids and Salts (Bile Acids)IBA 08/2020
1	Tryptophan HydroxylaseIBA 08/2020
1	Etoposide (VP 16)FDA LinkGeneric 05/2020
1	Carboplatin (JM8)FDA LinkGeneric 05/2020
1	PlatinumIBA 05/2020
1	Cyclin-Dependent Kinase 4IBA 01/2020
1	Neoprene (Polychloroprene)IBA 11/2019
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2019
1	Fluorouracil (Carac)FDA LinkGeneric 04/2019
1	folfirinoxIBA 04/2019
1	Gemcitabine FDA Link 04/2019
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 04/2019
1	Irinotecan (Camptosar)FDA LinkGeneric 04/2019
1	130-nm albumin-bound paclitaxelIBA 04/2019
1	MethyltransferasesIBA 01/2018
1	Temozolomide (Temodar)FDA LinkGeneric 01/2018
1	Hemoglobins (Hemoglobin)IBA 01/2018
1	O-(6)-methylguanineIBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	MesothelinIBA 01/2018
1	Differentiation AntigensIBA 01/2018
1	TOR Serine-Threonine KinasesIBA 10/2016
1	iodized salt (iodised salt)IBA 06/2016

Therapy/Procedure

8	Therapeutics 01/2023 - 07/2012
6	Drug Therapy (Chemotherapy) 02/2024 - 10/2016
4	Immunotherapy 01/2022 - 10/2018
2	Radiotherapy 05/2016 - 07/2012
1	Aftercare (After-Treatment) 01/2022
1	Diet Therapy (Therapy, Diet) 08/2020
1	Enzyme Replacement Therapy 08/2020
1	Pancreaticoduodenectomy 11/2019
1	Duration of Therapy 04/2019
1	Adjuvant Radiotherapy 01/2019